International
The Morning Science

What science found today

‹
 

Research

Mild Alzheimer's patients benefit from 40Hz sensory stimulation in national clinical trial

Medical Xpress ·

Mild Alzheimer's patients benefit from 40Hz sensory stimulation in national clinical trial

The Brief

  • Cognito Therapeutics announced the results of its pivotal clinical trial in mild Alzheimer's patients on November 16 at the Clinical Trials on Alzheimer's Disease conference in Boston.
  • The trial tested a noninvasive, device-based approach using 40Hz sensory stimulation, a technique first discovered at the Picower Institute. The provided sources do not give the trial's efficacy figures.

Why it matters

It reports pivotal-trial results for a noninvasive, device-based Alzheimer's treatment, a different category from drug therapies, so its outcomes will matter to researchers evaluating non-drug interventions.

Who’s affected

  • people with mild Alzheimer's disease and their caregivers
  • clinicians and researchers in neurodegenerative disease

At the Clinical Trials on Alzheimer's Disease conference in Boston Nov. 16, MIT spinoff company Cognito Therapeutics announced the results of its pivotal clinical trial of a noninvasive, device-based approach to Alzheimer's disease (AD) treatment first discovered in The Picower…

Timeline

  1. Cognito Therapeutics announced pivotal clinical trial results at the Clinical Trials on Alzheimer's Disease conference in Boston

  2. Medical Xpress - latest medical and health news stories

    Mild Alzheimer's patients benefit from 40Hz sensory stimulation in national clinical trial

How do you feel about this?

0 Comments

    Mild Alzheimer's patients benefit from 40Hz sensory stimulation in national clinical trial – The Morning Science